# DEMETHER (NCT06172127)

> PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06172127
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: MedSIR
- Conditions: HER2-positive Breast Cancer
- Interventions: Trastuzumab deruxtecan; Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection; Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
- Enrollment: 165
- Primary outcome: 1-year PFS rate
- Primary outcome: 3-year OS rate

## Commentary we found

- YouTube: 8
- X threads: 7
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=demether-nct06172127

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06172127", "email": "<work email>"}; the inbox owner confirms by the emailed link.